Verona Pharma Plc (LON:VRP)’s share price dropped 37.5% during trading on Monday . The stock traded as low as GBX 65 ($0.85) and last traded at GBX 65 ($0.85). Approximately 146,888 shares traded hands during mid-day trading, an increase of 195% from the average daily volume of 49,797 shares. The stock had previously closed at GBX 104 ($1.36).
VRP has been the topic of several research reports. Shore Capital restated a “buy” rating on shares of Verona Pharma in a research note on Wednesday, October 31st. Jefferies Financial Group reiterated a “buy” rating on shares of Verona Pharma in a research note on Friday, January 4th.
WARNING: This piece of content was originally published by WKRB News and is the sole property of of WKRB News. If you are accessing this piece of content on another domain, it was stolen and reposted in violation of United States and international copyright laws. The original version of this piece of content can be read at https://www.wkrb13.com/2019/01/14/verona-pharma-vrp-shares-down-37-5.html.
Verona Pharma Company Profile (LON:VRP)
Verona Pharma plc, a clinical stage biopharmaceutical company, develops and commercializes therapeutics to treat respiratory diseases. The company's product candidate is RPL554, an inhaled dual inhibitor of the enzymes phosphodiesterase 3 and 4, which has completed Phase I and IIa clinical trials that acts as a bronchodilator and an anti-inflammatory agent for the treatment of chronic obstructive pulmonary disease and cystic fibrosis.
Featured Story: Stock Symbol
Receive News & Ratings for Verona Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Verona Pharma and related companies with MarketBeat.com's FREE daily email newsletter.